← SynDRA
SULFISOXAZOLE ACETYL
SynDRA canonical compound SYN0023271 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · OTC |
| Mechanism of action | folic acid antagonist |
| Indication | meningitis | otitis | trachoma | urinary tract infections |
| Disease area | infectious disease | otolaryngology |
All known targets
- EDNRA
- EDNRB
- Ednra
- folP
- Bact folP
- HRH4
Mechanisms of action (all sources)
- folic acid antagonist
- folP INHIBITOR
- bacterial antifolate
- Bact folP INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Anti-Infective Agents
- Sulfonamide Antimicrobial
- Anti-Bacterial Agents
- Antiparasitic Agents
- Antiprotozoal Agents
- Coccidiostats
ATC classes
- J01E · SULFONAMIDES AND TRIMETHOPRIM
- S01A · ANTIINFECTIVES
Cross-references
Synonyms
- ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL
- ERYZOLE
- GANTRISIN
- GANTRISIN PEDIATRIC
- ILOSONE SULFA
- LIPO GANTRISIN
- PEDIAZOLE
- acetylsulfisoxazole
- gantrisin
- Acetyl sulfisoxazole
- Acetyl sulfafurazole
- Acetylsulfafurazole
- Acetylsulfisoxazole
- Sulfafurazole acetyl
- Sulfisoxizole acetyl
- NSC-759138
- Gantrisin
- Gantrisin pediatric
- Lipo gantrisin
- Sulfisoxazole acetyl component of eryzole
- Sulfisoxazole acetyl component of ilosone sulfa
- Sulfisoxazole acetyl component of pediazole
- ACETYL SULFISOXAZOLE
- Lipo Gantrisin
- acetylsulfafurazole
- WBT5QH3KED
- NSC 759138
- Sulfisoxazole acetyl (USP)
- Sulfisoxazole acetyl [USP]
- N-3,4-Dimethylisoxazol-5-yl-N-sulphanilylacetamide
- RefChem:56070
- Sulfisoxazole acetal
- Acetylgantrisin
- MFCD00072139
- Acetylsulfisoxazole (JAN)
- ACETYLSULFISOXAZOLE [JAN]
- UNII-WBT5QH3KED
Reported adverse events
- Angioedema
- Cough
- Crystalluria
- Headache
- Hepatitis
- Leukopenia
- Pseudomembranous colitis
- Stevens-Johnson syndrome
- Tachycardia
Look up SULFISOXAZOLE ACETYL in the interactive SynDRA portal →